logo
Gabon longs to cash in on sacred hallucinogenic remedy

Gabon longs to cash in on sacred hallucinogenic remedy

France 2410-05-2025
For centuries, religious devotees have eaten it -- a psychotropic shrub that users say has addiction-fighting powers.
It fascinates foreign visitors, psychiatric patients and rich pharmaceutical companies that want to market it.
Now this central African country, where its use is enshrined in ancestral tradition, is scrambling to avoid missing out on the boom.
Teddy Van Bonda Ndong, 31, an initiate in the Bwiti spiritual tradition, calls it "sacred wood". He consumes it in small amounts daily, he said, for his "mental and physical health".
"It has a lot of power to help human beings," added Stephen Windsor-Clive, a 68-year-old retiree.
"It's untapped. A mysterious force lies within this plant."
He travelled to Gabon from Britain and consumed iboga -- in a powder ground from its roots -- during a 10-day Bwiti ceremony.
He tried it with a view to adopting it as a treatment for his daughter, who suffers from mental illness.
Economic potential
Given the interest, Gabon is seeking to channel the plant onto the international marketplace.
Exports of iboga products, including its active ingredient ibogaine, are few and strictly regulated in the country.
It grows mostly in the wild, but "more and more effort is being made to domesticate the plant", said Florence Minko, an official in the forestry ministry.
Potentially toxic in high doses, ibogaine can have effects similar to LSD, mescaline or amphetamines, and cause anxiety and hallucinations.
But users believe it can help drug addicts kick their habit and treat post-traumatic stress and neurological illnesses.
Yoan Mboussou, a local microbiologist and Bwiti initiate, hopes to gain an export licence for the 500-milligram ibogaine capsules he produces at his laboratory near the capital Libreville.
He sells them in Gabon as a food supplement, declaring them to have "anti-fatigue, antioxidant and anti-addictive" qualities.
Iboga, he believes, "is a potential lever to develop the economy and the whole country".
Tradition and IP
Countries such as the United States and France class iboga as a narcotic because of health risks identified in studies, especially heart issues. But it is used in treatment centres in countries including the Netherlands, Mexico and Portugal.
Numerous studies have examined its effects -- both helpful and harmful -- and scientists have taken out dozens of international patents for ibogaine therapeutic treatments.
"Most of those are based on studies of iboga use by Gabonese people, particularly by Bwiti practitioners," said Yann Guignon, from the Gabonese conservation group Blessings Of The Forest.
Despite the plant's "colossal therapeutic benefits", "Gabon is clearly missing out on the economic potential of iboga," he added.
"It did not position itself in this market in time by developing productive iboga plantations, a national processing laboratory and a proper industrial policy."
Overseas laboratories meanwhile have worked out how to make synthetic ibogaine and to extract it from other plants, such as Voacanga africana.
That flowering tree is available in greater quantities in Ghana and Mexico, which "can produce ibogaine at unbeatable prices", said Guignon.
And "Gabonese traditional knowledge is not protected by intellectual property regulations."
Currently only one company in Gabon has a licence to export iboga products -- though Minko, from the forestry ministry, said the country hopes this number will rise in the coming years.
She said companies were likely to produce more, spurred by revenue guarantees under the Nagoya Protocol, an international agreement on biological diversity and resource-sharing.
She wants the country to obtain a "made in Gabon" certificate of origin for iboga.
"This is a huge resource for Gabon. We have drawn up a national strategy for the conservation and sustainable use of the product," she said.
"Gatherings will soon be organised, bringing together all the groups concerned: NGOs, traditional practitioners and scientists."
Soothing properties
After harvesting iboga to the sound of traditional harps and consuming it in the initiation ceremony, Stephen Windsor-Clive was convinced by the benefits of iboga.
"I definitely want to bring my daughter here and have her have the experience," he said.
"This is my last attempt to find something which might be of assistance to her."
Another visitor, Tafara Kennedy Chinyere, travelled from Zimbabwe to discover Gabon and found, in the initiation, relief from anxiety and his "inner demons".
"I feel good in my body, in myself," he said, sitting under a tree after the ceremony.
"I feel like the iboga helped me to let go of things that you no longer need in your life."
© 2025 AFP
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Endangered US contraceptives put 1.4 million women at risk, NGO claims
Endangered US contraceptives put 1.4 million women at risk, NGO claims

Euronews

time07-08-2025

  • Euronews

Endangered US contraceptives put 1.4 million women at risk, NGO claims

More than 1.4 million women and girls in Africa risk losing access to life-saving care if a stockpile of US-owned contraceptives currently stored in Europe are destroyed in accordance with US government plans, according to NGO International Planned Parenthood Federation (IPPF). The contraceptives, valued at $10 million (€8.5 million ) are currently stored in a warehouse in Belgium, but face destruction following the closure of key American aid agency United States Agency for International Development (USAID), as reported. Plans for them to be incinerated in France in accordance with US government plans have sparked widespread condemnation from civil society organisations and politicians, who are calling for the supplies to be preserved. The IPPF has attempted to purchase the stock from the US government but had its offer rejected. The products were originally intended for distribution to lower-income countries by the now dismantled USAID. Approximately 77% of the stock, many with expiration dates between 2027 and 2029, was intended for use in African nations including the Democratic Republic of the Congo (DRC), Mali, Kenya, Tanzania, and Zambia. 'We are facing a major challenge. The impact of the USAID funding cuts has already significantly affected the provision of sexual and reproductive health services in Tanzania - leading to a shortage of contraceptive commodities, especially implants," said Dr Bakari, Project Coordinator at UMATI, IPPF's Member Association in Tanzania. Tanzania was set to receive more than a million injectable contraceptives and 365,000 implants from the Brussels stockpile, accounting for more than 40% of the total shipment. These supplies represent over half of USAID's annual support to Tanzania's health system and 28% of the country's total annual need. 'In Kenya, the effects of US funding disruptions are already being felt. The funding freeze has caused stock-outs of contraceptives, leaving facilities with less than five months' supply instead of the required 15 months,' said Nelly Munyasia, executive director for the Reproductive Health Network in Kenya also member of IPPF.** She added that the withdrawal of USAID has created a 46% funding gap in Kenya's national family planning programme. The US has long been the largest bilateral donor to family planning, contributing $600 million annually which was 40% of global donor funding. The cancellation of pending procurement contracts has widened an existing global funding gap from $167 million to $210 million across 32 countries, according to the Reproductive Health Supplies Coalition (RHSC), a global partnership of public, private, and non-governmental organisations. The coalition also warned of broader effects of burning this stash. The group said that, when a woman's first choice of contraceptive is missing, she may opt for a less-preferred product, which could lead to a stock-out of that product if demand rises unexpectedly. 'When family planning stocks are compromised, the entire supply chain is at risk, requiring new funding, time, and coordination that cannot materialise at short notice,' they stated. The RHSC has estimated that failure to deliver this stockpile to its intended recipients could result in 362,000 unintended pregnancies, 161,000 unplanned births, and 110,000 unsafe abortions. Political opposition in Europe During a briefing in late July, US State Department spokesperson Thomas Pigott said officials were 'still in the process here in terms of determining the way forward' with regard to the Belgian stock. As the supplies are reportedly set to be transferred to France for destruction, French Green Party politicians have appealed to President Emmanuel Macron to intervene. 'We cannot allow Donald Trump's anti-choice agenda to unfold on our territory. And so today, France must mediate with the Commission,' MEP Mélissa Camara (France/The Greens), one of the signatories of the letter, told Euronews. "Unfortunately there is no legal basis for intervention by a European health authority, let alone the French national drug safety authority, to recover these medical products," the French health ministry told AFP. "Since contraceptives are not drugs of major therapeutic interest, and in this case, we are not facing a supply shortage, we have no means to requisition the stocks," it added. The ministry also said it had no information on where the contraceptives would be destroyed.

Contraceptives destroyed in silence: 'Can France accept to become the executor of a senseless policy imposed by the US?'
Contraceptives destroyed in silence: 'Can France accept to become the executor of a senseless policy imposed by the US?'

LeMonde

time01-08-2025

  • LeMonde

Contraceptives destroyed in silence: 'Can France accept to become the executor of a senseless policy imposed by the US?'

A stockpile of several million doses of contraceptives, valued at $9.7 million, financed by USAID and usable until 2031, is currently being incinerated in France. These products, originally intended for women in extreme poverty in countries in the Global South, are being destroyed for purely ideological reasons, at the request of the Trump administration. The service provider tasked with the incineration has not yet been identified. This human and environmental waste must be stopped immediately. Why is this happening? Because the US administration, following a blinkered ideological agenda, ordered their destruction as part of the dismantling of USAID. It even refused to transfer the stock to NGOs who were ready to transport and distribute it. This is not a public health issue or a logistical problem. It is a radical political choice. USAID's logistics program, which is usually operated by the company Chemonics, appears to be linked to this operation. However, this cannot be confirmed, since neither the name of the logistics provider nor the name of the incinerator has been made public. The stock, which was previously stored in Belgium, was transported to France in about 10 trucks at the end of July. The exact location of the incineration is deliberately undisclosed. Despite the scale of the operation, the company responsible for handling the medical waste has not been identified. We contacted four major French waste management companies to ask whether they were involved in this operation. All replied that they were not concerned. An economic and environmental absurdity As NGOs active in several African countries, we know exactly what a contraceptive shortage means: unintended pregnancies, abandoned children, unsafe abortions, and girls forced out of school at age 12. It also means women trapped in unwanted motherhood. Can France accept to become the executor of a senseless policy imposed by the US without reaction? This destruction is also an economic and environmental absurdity. It costs more ($167,000) than it would to redistribute contraceptives to countries experiencing shortages. Eliminating usable products that are urgently needed in empty health centers will also generate metric tons of CO₂. It's a total waste.

Swiss regulator approves first malaria treatment for newborn babies
Swiss regulator approves first malaria treatment for newborn babies

Euronews

time08-07-2025

  • Euronews

Swiss regulator approves first malaria treatment for newborn babies

Switzerland's drug regulator has approved the world's first malaria treatment for newborn babies, clearing the way for the medicine to become available in parts of Africa where the life-threatening disease is endemic. In a late-stage clinical trial, pharmaceutical giant Novartis showed the drug was safe and effective for babies weighing less than five kilograms, which they typically reach by two months of age. Traditionally, these infants have been given either a full or half-dose of the antimalarial drug intended for babies six months or older. But because newborns do not process medicines the same way, there is a higher risk of side effects. The lack of specialised treatment – and the fact that babies are not vaccinated until they are around five months old – has left the youngest infants relatively unprotected against malaria, a mosquito-borne disease that kills about 597,000 people per year. Most deaths are among children under five years old in Africa. It's not clear exactly how many babies are affected, but in 2023, there were an estimated 36 million pregnancies in 33 African countries where malaria is widespread. About one in three mothers were infected with malaria while pregnant, raising the risk that they will pass the disease along to their newborns, according to the World Health Organization (WHO). 'Every one of those [babies] is a potential target for malaria infection,' Dr Lutz Hegemann, president of Novartis' global health programme, told Euronews Health. 'We don't want to leave any patient behind, no matter how small they are'. Eight African countries – Burkina Faso, Ivory Coast, Kenya, Malawi, Mozambique, Nigeria, Tanzania, and Uganda – are expected to quickly approve the medicine as part of a partnership with Swissmedic, the Swiss drugs regulator. Hegemann said Novartis hopes to roll the medicine out there this autumn, with more countries to follow, on a not-for-profit basis. The medicine, known as Coartem Baby, is similar to Novartis' existing drug to treat uncomplicated malaria in young children, but it has a different dose and ratio of ingredients to prevent side effects in the youngest infants. It also has a sweet cherry flavour and can be dissolved in breast milk to make it easier to give to patients. 'These are small changes, but big steps,' Dr Quique Bassat, head of the Barcelona Institute of Global Health, told Euronews Health. While the number of newborns with malaria 'still remains relatively modest in terms of the overall burden, those cases need to be treated, and therefore we need better drugs,' he added. 'Now we have something which is perfectly suitable for that specific age group where there was a gap'. Bassat advised Novartis on the clinical trial, which was funded by the European Union and the Swedish International Development Cooperation Agency.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store